MYNZ (Mainz Biomed NV) Cash And Cash Equivalents : $6.24 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Cash And Cash Equivalents?

Mainz Biomed NV's quarterly cash and cash equivalents declined from Dec. 2023 ($7.07 Mil) to Jun. 2024 ($0.98 Mil) but then increased from Jun. 2024 ($0.98 Mil) to Dec. 2024 ($6.24 Mil).

Mainz Biomed NV's annual cash and cash equivalents declined from Dec. 2022 ($17.14 Mil) to Dec. 2023 ($7.07 Mil) and declined from Dec. 2023 ($7.07 Mil) to Dec. 2024 ($6.24 Mil).

Mainz Biomed NV Cash And Cash Equivalents Historical Data

The historical data trend for Mainz Biomed NV's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Cash And Cash Equivalents Chart

Mainz Biomed NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.12

8.73

17.14

7.07

6.24

Mainz Biomed NV Quarterly Data
	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial									10.91	9.32	7.07	0.98	6.24

Mainz Biomed NV Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Mainz Biomed NV (NAS:MYNZ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Mainz Biomed NV Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Mainz Biomed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Robert Koch Strasse 50, Sirius Gutenberg Park, Mainz, RP, DEU, 55129

Website

https://www.mainzbiomed.com

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.